Amazon’s online pharmacy aims to improve access and price transparency for insulin; cases of the COVID-19 Eris variant are increasing globally; the Department of Justice (DOJ) responds to pushbacks of Medicare's drug price negotiation program from the Chamber of Commerce (COC).
Amazon Pharmacy Automates Discount Coupons for Insulin and Diabetes Medicines
Amazon has introduced a new feature to its online pharmacy that automatically applies manufacturer-sponsored coupons to over 15 insulin and diabetes medicines, aiding patients in accessing discounts that were promised by major drug manufacturers, according to Reuters. The coupons are intended to reduce the cost of insulin to as low as $35 for a 1-month supply. The move comes in response to challenges patients faced in obtaining discounted insulin prices as advertised, with Amazon aiming to make the process more transparent and accessible for the 37 million Americans with diabetes.
WHO Designates Eris "Variant of Interest," Highlighting Potential Mutations
The World Health Organization (WHO) is closely monitoring the new COVID-19 variant called EG.5, also known as Eris, which is becoming more prevalent in countries like China and the United States, according to CNBC. Classified as a "variant of interest," EG.5 is being observed for any mutations that could have an impact on its severity or transmissibility. Although the variant has shown increased prevalence and immune escape properties, the WHO states there have been no reported changes in disease severity associated with EG.5. Vaccine manufacturers like Moderna, Pfizer, and Novavax are preparing to release reformulated vaccines targeting the XBB variants, to which EG.5 is related.
DOJ Counters Bid to Block Medicare Drug Price Negotiation Program
The Department of Justice (DOJ) has responded to the Chamber of Commerce's request for an injunction to halt implementation of the Medicare Drug Price Negotiation Program, according to The Hill. The Chamber had filed a motion claiming that the program would harm businesses and patients in the United States, but the DOJ's response argues that the Chamber lacks standing to file the lawsuit and asserts that pausing the program would be detrimental to the public's interest. The DOJ also highlights that the negotiated prices' impact on companies won't be felt until 2026 and that the case can be fully litigated by then and emphasizes that the program aims to control Medicare spending and make drugs more affordable for seniors.
What Mass General Brigham is Doing to Combat Prostate Cancer Disparities Among Men of Color
May 5th 2024Quoc-Dien Trinh, MD, MBA, chief of urology at Brigham & Women's Faulkner Hospital, highlighted successful efforts to improve prostate cancer care access for underserved communities in Massachusetts.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
AUA Posters Highlight Racial Gaps in PSA Screening, Prostate Cancer Risk
May 4th 2024Speakers discussed the disparities in prostate-specific antigen (PSA) screening rates among different racial groups and explored the potential of free PSA percentage as a predictive marker for future prostate cancer risk.
Read More